| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2006 |
| Sales | 1,750 | 2,820 | 3,140 | 1,560 | 323,770 |
| Sales Growth | -37.94% | -10.19% | +101.28% | -99.52% | unch |
| Net Income | -14,770 | -18,630 | -12,330 | -14,520 | 0 |
| Net Income Growth | +20.72% | -51.09% | +15.08% | unch | unch |
Fresh2 Group Limited American ADR (FRES)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fresh2 Group Limited is a biotechnology company focused on early cancer screening and detection. The Company is also entering the business-to-business e-commerce food business with the formation of its wholly-owned subsidiary Fresh2 Technology Inc and the acquisition of Fresh2 Ecommerce Inc. Fresh2 Group Limited, formerly known as AnPac Bio-Medical Science Co. Ltd., is based in NEW YORK.
Fiscal Year End Date: 12/31